Related Experiment Videos
Beta 2-microglobulin kinetics in end-stage renal failure.
R A Odell1, P Slowiaczek, J E Moran
1Centre for Biomedical Engineering, University of New South Wales, Kensington, Australia.
Kidney International
|May 1, 1991
Summary
Beta 2-microglobulin (beta 2m) production is normal in hemodialysis patients. Non-renal clearance is significant, limiting extracorporeal removal to approximately 50% of weekly beta 2m production.
Area of Science:
- Nephrology
- Biochemistry
- Pharmacokinetics
Background:
- Beta 2-microglobulin (beta 2m) is a protein that accumulates in patients with impaired renal function.
- Understanding beta 2m kinetics is crucial for managing dialysis patients.
Purpose of the Study:
- To investigate the kinetics of beta 2-microglobulin (beta 2m) in hemodialysis patients.
- To determine the non-renal clearance and generation rate of beta 2m.
- To assess the efficacy of hemodialysis in removing beta 2m.
Main Methods:
- Isolated and radiolabeled human beta 2m with 125I.
- Administered radiolabeled beta 2m to five anephric/anuric hemodialysis patients.
- Measured plasma activity over 72 hours and assessed beta 2m clearance during low-flux and high-clearance dialysis.
- Utilized a three-compartment, variable volume model to analyze pharmacokinetic data.
Main Results:
- Endogenous beta 2m levels were elevated (56 +/- 6 mg/liter).
- Non-renal clearance of beta 2m was 3.0 +/- 0.4 ml/min.
- Beta 2m generation rate was similar to normal subjects (9.9 +/- 1.7 mg/hr).
- High-clearance dialysis achieved a beta 2m clearance of 19 ml/min, removing ~50% of weekly production.
Conclusions:
- Beta 2m production is not increased in hemodialysis patients.
- Significant non-renal clearance of beta 2m occurs.
- Extracorporeal removal of beta 2m by hemodialysis is limited.